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Abstract A non-obese diabetic (NOD) mouse-derived embryo-
nic stem (ES) cell line has been stably maintained in an
undifferentiated state with a characteristic ES cell-like morphol-
ogy, expressing the stem cell marker alkaline phosphatase, and
displaying a normal diploid karyotype. After injecting the NOD-
ES cells into blastocysts, chimeric mice were obtained. Small but
significant numbers of lymphocytes expressed the NOD-derived
MHC allele. When a chimeric mouse was mated with C57BL/6
mice, an agouti mouse was obtained, having the NOD-derived
H-2 I-Ag7L haplotype. Thus, an NOD-ES cell line which can
differentiate into lymphocytes with potential for germ line
transmission was successfully established.
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1. Introduction
Embryonic stem (ES) cells are pluripotent cells derived
from the inner cell mass of the preimplantation mouse em-
bryo. ES cells can be stably propagated in an undi¡erentiated
state in vitro using a feeder layer and/or leukemia inhibitory
factor (LIF), and they also retain the ability to di¡erentiate
into all cell types found in embryonic and adult mice in vivo
[1^5]. The genetic manipulation of ES cells by homologous
recombination between the genomic locus and homologous
DNA introduced into the cells has enabled the introduction
of selected mutations into the mouse germ line [1^4]. The
derived mutant mice have tremendously accelerated our
understanding of the function of the targeted genes in vivo,
and allowed the creation of mouse models for human diseases,
clarifying the roles of speci¢c genes in development, metabolic
pathways and immunologic functions [1^4]. However, all the
germ line competent embryonic stem cell lines in widespread
use, such as ES-D3, CCE, E14, and AB1 [6^9], have been
derived from blastocysts of the 129/Sv mouse strain. No ES
cell lines derived from disease model animals have yet been
reported. The ES lines derived from 129/Sv mice cannot yet be
used directly for immunological and/or disease model studies,
since they require extensive backcrossing to the desired mouse
strain, which is very time-consuming and costly. Therefore the
general use of ES cell technology remains limited in the im-
munologic ¢eld and animal models for human diseases.
The NOD mouse is a representative autoimmune animal
model in which the development of insulitis is associated
with the destruction of pancreatic L cells, thus leading to
type 1 diabetes [10^12]. The development of autoimmunity
in this animal model is controlled by multiple immune mech-
anisms [11,12] and many diabetes associated idd genetic loci
(18 loci at present) have been reported [13,14]. Considerable
evidence also suggests that cooperation between CD4 and
CD8 T cells is required to promote the development of insu-
lin-dependent diabetes mellitys (IDDM) in NOD mice and
that islet L cell destruction is mediated by both CD4+ and
CD8+ T cells [15,16]. Included among the e¡ector cells of
IDDM in NOD mice are CD4+ Th1 cells stimulated by in-
terleukin-12 (IL-12), which preferentially secrete interferon-Q
(IFN-Q) and tumor necrosis factor K, whereas the susceptibil-
ity to IDDM may be regulated by CD4+ Th2 cells, which
preferentially secrete IL-4, IL-5, IL-6, IL-10 and IL-13
[12,17,18]. A high ratio of IFN-Q/IL-4 expression in islet in-
¢ltrating lymphocytes is predictive of both the onset of de-
structive insulitis and a high incidence of IDDM [19]. Thus, it
is evident that lymphocyte functions play a major role in
controlling the autoimmune diabetes in NOD mice. However,
the exact role of each T cell subpopulation and/or cytokines in
vivo still remains to be clari¢ed. In order to address the spe-
ci¢c role of genes and molecules of NOD mice in vivo, it is
imperative to be able to perform genetic manipulation of
NOD mice.
Only a few gene-targeted NOD mice have been reported,
and these mice demonstrated the importance of MHC class I
expression and B cells in disease pathogenesis, while IL-4 was
found to be less important [20^23]. In these mutant mice, gene
targeting was originally performed in 129/Sv mouse derived-
ES cells, followed by backcrossing the gene-targeted mice to
NOD mice in order to establish a congenic strain [20^23].
However, the possibility remains that the backcrossed mice
are not completely congenic and may still lack disease-asso-
ciated genes, since the autoimmune diabetes in NOD mice is
known to be polygenic [13,14]. In addition, it is very time
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consuming and costly to perform backcrossing NOD mice,
which must be performed for 10 generations to achieve a
99.9% probability that the backcrossed mice are congenic at
all loci, requiring 3^4 years [24,25]. Even in speed congenic
mice using marker-associated selection protocols, a total
of ¢ve generations (four backcrossings) are needed, to
achieve 6 0.5% donor genome contamination, requiring a pe-
riod of 1.5^2 years [24,25]. Indeed, our group reported that a
mild but apparent presence of insulitis in B cell-de¢cient NOD
mice in eight times backcrossed mutant NOD mice [23], while
another group reported a lack of insulitis and diabetes in B
cell-de¢cient speed congenic NOD mice. Furthermore, anoth-
er group reported that insulitis and diabetes in B cell-de¢cient
NOD mice still remained [26]. Thus, the consequence of B cell
de¢ciency in NOD mice remains somewhat controversial, thus
suggesting that the backcrossed mice may not have the same
genetic background. In addition, since the autoimmunity in
NOD mice is dependent on the abnormal immune response
mediated by the lymphocytes [12,13,15^18], it would be of
potential importance to perform genetic manipulation of lym-
phocytes and observe the immunologic consequences of the
immune system of NOD mice. This becomes possible by ma-
nipulation of lymphocytes controlling the disease develop-
ment. To exclude the possible in£uence of undetermined genes
in a congenic strain and to reduce the time and cost, the
establishment of NOD mouse derived ES cells with a potential
for germ line transmission has long been anticipated, although
no NOD mouse-derived ES cell line has yet been reported.
Here we report the establishment of an ES cell line derived
from NOD mice and its capability of di¡erentiation into lym-
phocytes and of germ line transmission.
2. Materials and methods
2.1. Cell culture conditions
Dulbecco’s modi¢ed Eagle’s medium with high glucose (DMEM)
supplemented with 20% fetal bovine serum (Gibco, prescreened for
the ability to support the growth of ES cells), 50 U/ml of penicillin
and 10 Wg/ml of streptomycin (Gibco), with leukemia inhibitory factor
(ESGRO) at a concentration of 104 U/ml, 5.5U1035 M 2-mercapto-
ethanol solution, 0.5% of non-essential amino acid solution (Gibco),
and nucleosides as described elsewhere [27] (complete medium) was
used to isolate and propagate ES cells. A solution of 0.25% trypsin in
0.04% EDTA was used for routine subculture, in which the culture
medium was discarded, warmed phosphate bu¡ered saline (PBS) at
37‡C was added to the cells, and then warmed EDTA-trypsin solution
was added to the culture. Following 3 min of incubation, complete
medium with fetal bovine serum was added and the cells were dis-
persed. The ES cells were incubated at 37‡C in an atmosphere of 5%
CO2 in air.
2.2. Preparation of feeder layers
Primary embryonic ¢broblasts were previously prepared from ex-
planted 13^14 day BALB/c mouse fetuses. A con£uent ¢broblast cul-
ture was then treated with 10 Wg/ml of mitomycin C (MMC) for 2 h
and was washed three times with PBS. The MMC-treated ¢broblasts
were detached with EDTA-trypsin and 5U105 cells/ml were then
seeded onto gelatin coated dishes (Sumilon, Japan).
2.3. Isolation of blastocysts
Between 3 days and 3.5 days after mating, the oviduct of pregnant
NOD mice was £ushed with complete medium using a 30 G needle
and blastocysts were obtained. This procedure increased the number
of eluting blastocysts that could be harvested.
2.4. In vitro characterization of ES cells
The established ES cells were stained for the presence of alkaline
phosphate in the cytoplasm using the alkaline phosphatase staining
kit (Muto Chem. Japan). For chromosome counts, ES cells at the
17th and 27th passage level were pretreated for 2 h with colcemid
(0.1 Wg/ml) and metaphase spreads were prepared and stained with
Giemsa. Finally, the number of chromosomes was counted.
2.5. Generation of injection chimeras
Host embryos were recovered at the morula stage from the oviducts
of hormonally treated C57BL/6 females and cultured overnight. Blas-
tocysts were transferred together with suspended ES cells at the 24th
passage level into drops of injection medium. About 10^20 ES cells
were injected into each blastocyst. After a recovery period of about
2 h, the injected blastocysts were transferred into the uterine horn of
pseudopregnant ICR foster mothers. Chimeric o¡springs were identi-
¢ed by a mixed white albino coat color on a black background.
Chimeric male mice were further mated to C57BL/6 mice to obtain
an agouti mouse.
2.6. PCR for detection of NOD-speci¢c I-Ag7L genes
I-A genes of the class II molecules were determined as previously
described [20]. PCR for genomic DNA was performed by using pri-
mers with additional EcoRI sites speci¢c for I-Ag7L (5P-A
g7
L : 5P-TCTA-
GAATTCACAGCGACGTGGGCGAGT-3P and 3P-Ag7L : 5P-TCTA-
GAATTCCGTAGTTGTGTCTGCACG-3P). The I-AL genes were
ampli¢ed as follows: denaturing at 94‡C for 1.5 min, annealing at
55‡C for 1.0 min and extension at 72‡C for 1.0 min, for 25 cycles
on a DNA thermal cycler [20,23].
2.7. Flow cytometric analysis
Peripheral blood was taken from the periorbital sinus, followed by
lysis of red blood cells with ammonium chloride. For £ow cytometric
analysis, peripheral blood leukocytes of mice were ¢rst treated with
1 Wg/106 cells of rat anti-mouse CD16/CD32 (FcQ III/II receptor)
monoclonal antibody (PharMingen, San Diego, CA, USA) to reduce
Fc receptor-mediated non-speci¢c binding of following antibodies.
Then, the cells were stained with 0.5 Wg/106 cells of biotin-labeled
anti-H-2Kd (SF1-1.1) (PharMingen), or with 1.0 Wg/106 cells of £uo-
rescein isothiocyanate (FITC)-labeled anti-H-2Kb (AF6-88.5) (Phar-
Mingen) mAb. The cells were washed with PBS containing 2% fetal
bovine serum and 0.1% NaN3, followed by 0.5 Wg/106 cells of strep-
tavidin-Red 670 (Gibco, Grand Island, NY, USA) staining. The cells
were analyzed by a £ow cytometer (Becton Dickinson).
3. Results
3.1. Isolation of ES cells
In the ¢rst series of experiments, four ES cell lines were
Fig. 1. NOD mouse-derived ES cell line, formation of chimeric mice
and germ line transmission. a: Growing colonies of the established
ES cell line derived from a NOD mouse (2 day culture) (U100). b:
Alkaline phosphatase staining (U400). c: A representative karyo-
type of the NOD mouse-derived ES cell line (U1000). d: Mice de-
rived from the NOD ES cell line. A: agouti mouse, germ line trans-
mission, B: control C57BL/6 mouse, C: chimeric mouse, N: control
NOD mouse.
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isolated from 138 blastocysts. Three lines lost the ES-like
characteristics during further passage. The remaining cell
line morphologically resembled ES cells, however, it had de-
veloped a tetraploid karyotype, and was thus abandoned. In
the second series of experiments, 181 blastocysts were cul-
tured, and one cell line exhibited the characteristic morphol-
ogy of ES cells (Fig. 1a), and expressed a stem cell marker,
alkaline phosphatase in its cytoplasm (Fig. 1b). More than
90% of the ES cells possessed 40 chromosomes with a Y
chromosome, 21/23 (91%) at the 17th and 33/35 (94%) at
the 27th passage, and the cell line displayed a normal diploid
karyotype (Fig. 1c). The cell line was stably maintained in a
morphologically undi¡erentiated state for over 27 passages.
3.2. Production of chimeric mice and di¡erentiation into
lymphocytes in vivo
Using the NOD mouse-derived cell line at the 24th passage
level, we obtained 22 chimeric mice (nine males, 13 females)
(Fig. 1d) out of 90 o¡spring. Based on skin condition three
(one male, two females) of 22 mice expressed more than 80%
chimerism (Fig. 1d), six (one male, ¢ve females) showed 50^
80% chimerism, and six (four males, two females) showed 30^
50%. Seven (two males, ¢ve females) showed less than 30%
(Table 1). To assess whether the ES cells could di¡erentiate
into lymphoid tissue, we analyzed the peripheral blood lym-
phocytes of chimeric mice expressing over 80% skin chimer-
ism. A small but signi¢cant number of peripheral blood lym-
phocytes expressed H-2Kd but not H-2Kb in all chimeric mice
examined (Fig. 2), indicating that ES cells derived from NOD
mice maintain the potential to di¡erentiate into lymphocytes.
3.3. Germ line transmission
The highly chimeric male mouse (more than 80%) was
mated with C57BL/6 female mice. One out of 97 o¡spring
was agouti in appearance (Fig. 1d). Genomic DNA analysis
of the agouti mouse by PCR revealed the presence of the H-2
I-Ag7L gene, which was derived from the NOD mouse (Fig. 3a).
In addition, a £ow cytometric analysis showed coexpression of
both H-2Kb and H-2Kd class I molecules (Fig. 3b), thus sug-
gesting that the ES cell DNA was transmitted through the
germ line.
4. Discussion
We successfully established an ES cell line with a potential
for germ line transmission. Peripheral blood of chimeric mice
contained lymphocytes derived from the NOD ES cell line,
indicating that it could di¡erentiate into lymphoid tissues. ES
cell technology has greatly contributed to advances in analysis
of in vivo function of genes [1^4]. For that purpose, pluripo-
tent ES cells derived from 129/Sv mice have been widely uti-
lized, but no ES cell line derived from a disease model animal
has been reported. This has hampered the overall use of ES
technology in animal models for human diseases. ES cells
derived from more well-studied mouse strains could hasten
investigation of in vivo gene function. In order to apply the
ES cell technology in the immunologic ¢eld, Ledermann and
Burki reported the establishment of a germ line-competent ES
cell line derived from the C57BL/6 mouse [5]. They used a
preconditioned medium obtained from 5637 human bladder
carcinoma cells and the explanted embryonic cells of CD-1
mice as a feeder layer. LIF has been reported to be capable
of replacing the feeder layers of embryonic ¢broblasts and
conditioned medium [28,29]. Independently of the approach
chosen, the establishment of embryonic stem cell lines largely
depends on the establishment of optimal culture conditions
[5^9]. In the present study, we used both an ES medium con-
taining 1U104 u/ml of LIF and embryonic ¢broblasts derived
from BALB/c mice as a feeder layer. These culture conditions
were essential for supporting the growth of the NOD mouse-
derived ES cells, while also maintaining them in an undi¡er-
entiated state. When deprived of either LIF or the feeder
layer, the ES cells tended to begin to di¡erentiate into epithe-
lial and other tissues, thus emphasizing the importance of the
culture conditions for isolating and propagating the estab-
Table 1
Formation of chimeric mice from the NOD mouse-derived ES cell
line
Skin chimerism Number of chimeric mice
w80% 3 (7 1, 6 2)
50^80% 6 (7 1, 6 5)
30^;50% 6 (7 4, 6 2)
6 30% 7 (7 2, 6 5)
Total 22 (7 8, 6 14)
Fig. 2. Flow cytometric analysis of peripheral lymphocytes in chi-
meric mice. A low percentage of peripheral blood lymphocytes of
chimeric mice expressed H-2Kd without H-2Kb, a surface phenotype
that is derived from the NOD ES cells.
Fig. 3. a: PCR detection of the NOD mouse-derived H-2 I-Ag7L
gene in the peripheral lymphocytes of an agouti mouse. b: Flow cy-
tometric analysis of the peripheral lymphocytes of an agouti mouse
revealed the coexpression of both H-2Kb and H-2Kd class I mole-
cules.
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lished ES cell line from NOD mice. The NOD ES cell line had
a modal chromosome number of 40 with a Y chromosome,
indicating a male genotype. This genotype is consistent with
that of previous ES cell lines, which are predominantly male,
probably due to chromosome instability [5^9].
In the present study, we described a NOD mouse-derived
ES cell line which is competent for di¡erentiation into lym-
phoid tissue in chimeric mice. Since lymphocytes are impera-
tive for the development of autoimmune diabetes in NOD
mice, this cell line will be useful for the genetic manipulation
of lymphocytes controlling the disease. The roles of the ma-
nipulated lymphocytes can be investigated by transferring
them into immunode¢cient NOD mice, such as T cell-de¢-
cient, severe combined immunode¢cient (SCID), or B cell-de-
¢cient NOD mice to clarify the in vivo role of genes and
molecules of lymphocytes responsible for disease develop-
ment. In addition, the germ line transmissible NOD ES cells
may also be useful for the direct genetic manipulation of the
NOD mouse by homologous recombination strategies, or may
further be useful for the conditional gene knockout using the
Cre-loxP system [30]. Although the NOD ES line successfully
exhibited germ line transmission, the e⁄ciency was low. Sim-
ilarly, although a germ line-competent ES cell line has been
successfully established from C57BL/6 mice, the transmissibil-
ity was reported to be low, possibly due to a diminished
capacity to di¡erentiate into sperm [5]. Only a few ES cell
lines are able to e¡ectively transmit to the germ line except
for ES lines derived from 129/Sv mice, which are characterized
by a high incidence of spontaneous testicular teratomas or
teratocarcinomas [27]. It is thus possible that the di¡erentia-
tion potential of germ cells derived from ES cells of mice
other than 129/Sv mice might be inherently lower. We are
now subcloning the ES cell line based on the morphological
characteristics with clear margins, and we have thus obtained
four sublines. An attempt to ¢nd an ES cell line with in-
creased germinal transmission capability is also currently
under way.
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